Actavis Confirms Favorable Ruling in Generic Yaz Patent Suit

Actavis (NYSE: ACT ) today announced that it has re-launched Vestura™ (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz® oral contraceptive product, following a ruling from the United States Court of Appeals for the Federal Circuit that United States Patent